Posado-DomÃnguez, L.; Escribano-Iglesias, M.; Bellido-Hernández, L.; León-Gil, J.G.; Gómez-Muñoz, M.A.; Gómez-Caminero López, F.; MartÃn-Galache, M.; Inés-Revuelta, S.M.; Fonseca-Sánchez, E.
Inflammatory Mesenteric Disease and Sarcoidosis-like Reaction in a Patient with Lung Adenocarcinoma Who Received Pembrolizumab: Paraneoplastic Syndrome, Secondary to Checkpoint Inhibitor or Chance Finding? Curr. Oncol. 2024, 31, 7319-7329.
https://doi.org/10.3390/curroncol31110540
AMA Style
Posado-DomÃnguez L, Escribano-Iglesias M, Bellido-Hernández L, León-Gil JG, Gómez-Muñoz MA, Gómez-Caminero López F, MartÃn-Galache M, Inés-Revuelta SM, Fonseca-Sánchez E.
Inflammatory Mesenteric Disease and Sarcoidosis-like Reaction in a Patient with Lung Adenocarcinoma Who Received Pembrolizumab: Paraneoplastic Syndrome, Secondary to Checkpoint Inhibitor or Chance Finding? Current Oncology. 2024; 31(11):7319-7329.
https://doi.org/10.3390/curroncol31110540
Chicago/Turabian Style
Posado-DomÃnguez, Luis, MarÃa Escribano-Iglesias, Lorena Bellido-Hernández, Johana Gabriela León-Gil, MarÃa Asunción Gómez-Muñoz, Felipe Gómez-Caminero López, MarÃa MartÃn-Galache, Sandra M. Inés-Revuelta, and Emilio Fonseca-Sánchez.
2024. "Inflammatory Mesenteric Disease and Sarcoidosis-like Reaction in a Patient with Lung Adenocarcinoma Who Received Pembrolizumab: Paraneoplastic Syndrome, Secondary to Checkpoint Inhibitor or Chance Finding?" Current Oncology 31, no. 11: 7319-7329.
https://doi.org/10.3390/curroncol31110540
APA Style
Posado-DomÃnguez, L., Escribano-Iglesias, M., Bellido-Hernández, L., León-Gil, J. G., Gómez-Muñoz, M. A., Gómez-Caminero López, F., MartÃn-Galache, M., Inés-Revuelta, S. M., & Fonseca-Sánchez, E.
(2024). Inflammatory Mesenteric Disease and Sarcoidosis-like Reaction in a Patient with Lung Adenocarcinoma Who Received Pembrolizumab: Paraneoplastic Syndrome, Secondary to Checkpoint Inhibitor or Chance Finding? Current Oncology, 31(11), 7319-7329.
https://doi.org/10.3390/curroncol31110540
